All articles

Medication · 7 min read · Updated November 21, 2026

GLP-1 medications: FDA label facts in one table

Wegovy, Ozempic, Zepbound and Mounjaro side by side: what each is approved for, how the dose steps up, and the warnings on the label.

GLP-1 medications: FDA label facts in one table

Semaglutide is sold as Wegovy and Ozempic. Tirzepatide is sold as Zepbound and Mounjaro. Wegovy and Zepbound are the ones approved for weight reduction. Ozempic and Mounjaro are approved for type 2 diabetes. All four injections are taken once a week, start at a low dose that is raised about every 4 weeks, and carry a boxed warning about thyroid C-cell tumors. The table sets out what each FDA label says.

Last reviewed against FDA labels on November 21, 2026. These figures are for the brand-name drugs. Compounded semaglutide and tirzepatide are not FDA-approved, and no FDA label describes them.

The table

Wegovy, Ozempic, Zepbound and Mounjaro injections compared, from their FDA labels
Wegovy (semaglutide)Ozempic (semaglutide)Zepbound (tirzepatide)Mounjaro (tirzepatide)
Approved forWith a reduced-calorie diet and more physical activity: weight reduction and keeping it off in adults and children 12 and older with obesity, and in adults with overweight plus at least one weight-related condition. Lowering the risk of major cardiovascular events in adults with cardiovascular disease and obesity or overweight. A liver disease, MASH with moderate to advanced fibrosis, in adultsWith diet and exercise: blood sugar control in adults with type 2 diabetes. Lowering the risk of major cardiovascular events in adults with type 2 diabetes and cardiovascular disease. Lowering the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Weight loss is not on the listWith a reduced-calorie diet and more physical activity: weight reduction and keeping it off in adults with obesity, or with overweight plus at least one weight-related condition. Moderate to severe obstructive sleep apnea in adults with obesityWith diet and exercise: blood sugar control in adults and children 10 and older with type 2 diabetes. Lowering the risk of major cardiovascular events in adults with type 2 diabetes at high risk of them. Weight loss is not on the list
Starting dose0.25 mg once a week for 4 weeks0.25 mg once a week for 4 weeks2.5 mg once a week for 4 weeks. The label says 2.5 mg is not a maintenance dose2.5 mg once a week
Dose steps0.5 mg, then 1 mg, then 1.7 mg, each for 4 weeks. Maintenance from week 170.5 mg after 4 weeks. If more blood sugar control is needed, 1 mg and then 2 mg, each after at least 4 weeks on the dose before5 mg after 4 weeks. Then up in 2.5 mg steps, each after at least 4 weeks on the current doseUp in 2.5 mg steps, each after at least 4 weeks on the current dose, if more blood sugar control is needed
Maintenance and maximum1.7 mg or 2.4 mg a week, with 2.4 mg recommended. For weight reduction in adults who have tolerated 2.4 mg for at least 4 weeks, the dose may go up to a maximum of 7.2 mg a week0.5 mg, 1 mg or 2 mg a week. Maximum 2 mg5 mg, 10 mg or 15 mg a week for weight. 10 mg or 15 mg for sleep apnea. Maximum 15 mgMaximum 15 mg a week in adults and 10 mg in children
How oftenOnce a week, on the same day, at any time of day, with or without mealsOnce a week, on the same day, at any time of day, with or without mealsOnce a week, at any time of day, with or without mealsOnce a week, at any time of day, with or without meals
Missed doseTake it as soon as possible if the next dose is more than 2 days away. Otherwise skip itTake it within 5 days. After that, skip itTake it within 4 days. After that, skip itTake it within 4 days. After that, skip it
Boxed warningRisk of thyroid C-cell tumorsRisk of thyroid C-cell tumorsRisk of thyroid C-cell tumorsRisk of thyroid C-cell tumors
Must not be used byAnyone with a personal or family history of medullary thyroid cancer, or with MEN 2. Anyone who has had a serious allergic reaction to semaglutideSame as WegovyAnyone with a personal or family history of medullary thyroid cancer, or with MEN 2. Anyone with a known serious allergy to tirzepatideSame as Zepbound
Main warningsPancreatitis. Gallbladder disease. Low blood sugar, mainly with insulin or a sulfonylurea. Kidney injury from dehydration. Severe stomach and gut reactions. Serious allergic reactions. Worsening diabetic eye disease in people with type 2 diabetes. A faster heart rate. Food left in the stomach during anesthesia or deep sedationThe same list as Wegovy, without the heart rate warningThe same list as Wegovy, without the heart rate warningThe same list as Wegovy, without the heart rate warning
Side effects in 5% or moreNausea, diarrhea, vomiting, constipation, stomach pain, altered skin sensation, headache, tiredness, indigestion, dizziness, bloating, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, reflux, hair lossNausea, vomiting, diarrhea, stomach pain, constipationNausea, diarrhea, vomiting, constipation, stomach pain, indigestion, injection site reactions, tiredness, allergic reactions, belching, hair loss, refluxNausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, stomach pain

Same ingredient, different labels

Wegovy and Ozempic both contain semaglutide. Zepbound and Mounjaro both contain tirzepatide. The FDA approves a product for specific uses at specific doses, so two products with the same ingredient can have different approved uses, different top doses and different side effect lists, because each was tested in different people. Each list in the last row comes from that product's own trials, which is why they can't be compared line by line.

One naming point: tirzepatide is usually grouped with the GLP-1 medicines, but its labels describe it as acting on two receptors, GIP and GLP-1. Semaglutide acts on GLP-1 alone.

We go through that difference in semaglutide and tirzepatide compared.

How the dose steps work

All four labels start low and raise the dose in steps of at least 4 weeks. The labels give the reason: stepping up slowly lowers the risk of stomach and gut side effects. The Wegovy label says a step can be delayed by 4 weeks if a dose is not tolerated, and the Zepbound label says a lower maintenance dose can be considered. The schedule in the table is the label's. The dose a person ends up on is a prescriber's decision.

The boxed warning

A boxed warning is the strongest warning the FDA puts on a label. All four carry the same one. In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. The labels say it is unknown whether they cause these tumors, including medullary thyroid cancer, in people.

Because of that, none of the four may be used by someone with a personal or family history of medullary thyroid cancer, or with a condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The labels list the symptoms to report: a lump in the neck, trouble swallowing, shortness of breath, or hoarseness that does not go away.

The warnings in plain terms

  • Pancreatitis. The labels say to stop the medicine if it is suspected. The sign they describe is severe stomach pain that does not go away, sometimes reaching the back, with or without vomiting.
  • Gallbladder problems, including gallstones.
  • Low blood sugar, mainly in people who also take insulin or a sulfonylurea.
  • Kidney injury. The labels link it to dehydration from nausea, vomiting or diarrhea.
  • Severe stomach and gut reactions. None of the four is recommended for people with severe gastroparesis.
  • Serious allergic reactions.
  • Worsening of diabetic eye disease in people with type 2 diabetes.
  • Anesthesia. These medicines slow stomach emptying, and the labels say to tell your healthcare providers you take one before any planned surgery or procedure.

Wegovy also comes as a tablet

The current Wegovy label covers a once-daily tablet as well as the weekly injection. The tablet starts at 1.5 mg a day and steps up every 30 days to 4 mg, then 9 mg, then a maintenance dose of 25 mg. It is taken in the morning on an empty stomach with no more than 4 ounces of water, at least 30 minutes before food, drink or other medicines taken by mouth. The table above covers the injections only.

What these labels do not cover: compounded versions

Compounded semaglutide and tirzepatide are prepared by pharmacies for individual prescriptions. They are not FDA-approved, and the FDA does not review them for safety, effectiveness or quality before they are dispensed. Everything in the table describes the brand-name drugs. It should not be read as a description of a compounded product, or as evidence of what one will do.

The FDA has said it has received reports of side effects, some serious, in people given compounded semaglutide or tirzepatide at doses above the approved label, or with the dose raised faster than the label schedule. It has also received reports of dosing errors, some from people measuring and injecting the wrong dose themselves. If you are prescribed a compounded version, ask your provider or pharmacist to show you exactly how to measure your dose.

The semaglutide and tirzepatide that EverSlim's providers prescribe are compounded. EverSlim does not sell Wegovy, Ozempic, Zepbound or Mounjaro. You can see how EverSlim's compounded GLP-1 treatment works and who can get it.

This page is a reference, not medical advice. Whether one of these medicines is right for you, and at what dose, is a decision for a licensed provider who knows your health history.

Common questions

Is Ozempic approved for weight loss?

No. The Ozempic label lists uses in adults with type 2 diabetes: blood sugar control, lowering cardiovascular risk and lowering kidney risk. Wegovy is the semaglutide product the FDA has approved for weight reduction, and Zepbound is the tirzepatide one.

What is the starting dose of semaglutide and tirzepatide?

On the brand-name labels, semaglutide injections (Wegovy and Ozempic) start at 0.25 mg once a week and tirzepatide injections (Zepbound and Mounjaro) start at 2.5 mg once a week. The dose is then raised in steps of at least 4 weeks. Your prescriber sets your dose.

Do all GLP-1 medications have a boxed warning?

All four covered here do. Wegovy, Ozempic, Zepbound and Mounjaro carry a boxed warning about the risk of thyroid C-cell tumors, based on rodent studies. The labels say it is unknown whether the medicines cause these tumors in people.

Do these label facts apply to compounded semaglutide or tirzepatide?

No. The figures come from the FDA labels of the brand-name drugs. Compounded versions are not FDA-approved, are not reviewed by the FDA for safety, effectiveness or quality, and have no FDA label of their own.

Sources

  1. WEGOVY (semaglutide) injection and tablets, prescribing information (Novo Nordisk). FDA label, DailyMed
  2. OZEMPIC (semaglutide) injection, prescribing information (Novo Nordisk). FDA label, DailyMed
  3. ZEPBOUND (tirzepatide) injection, prescribing information (Eli Lilly). FDA label, DailyMed
  4. MOUNJARO (tirzepatide) injection, prescribing information (Eli Lilly). FDA label, DailyMed
  5. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. FDA
  6. Compounding and the FDA: Questions and Answers. FDA

Compounded medications are prescribed at a licensed provider's discretion and are not FDA-approved. Prescription medications are filled by licensed compounding pharmacies across the US, and packaging will vary. Individual results vary. This page is not medical advice.

See if a GLP-1 plan is right for you.

Check your eligibility for free in about 60 seconds. No insurance required.

Keep reading